Abbott India shares rise after company posts strong Q1 performance

Abbott India, on Tuesday (August 12), reported strong growth on a year-on-year basis across key financial metrics in the first quarter ended June 30, 2025. The company’s net profit rose 11.6% to ₹366 crore from ₹328 crore in the same period last year.

Shares of the company are trading in green at ₹33,600, up 1.81%, on the BSE. The stock has gained as much as 12% year-to-date.

During the June quarter, the company’s top line also grew at a similar pace as the net profit, recording an 11.6% increase to ₹1,738.4 crore from ₹1,557.6 crore a year ago. The earnings before interest, taxes, depreciation and amortisation (EBITDA) jumped 14% to ₹445.7 crore in the April to June period.

However, the EBITDA margins improved only slightly to 25.6% from 25.1% last year.

Separately, the company’s board approved the appointment of Darshan Gada as an Additional (Non-Executive) Director of the company with effect from August 18, 2025. The appointment is subject to the approval of the shareholders.

In June, the Indian arm of the American multinational announced that it would market MSD Pharmaceuticals’ oral anti-diabetes medications in India, including sitagliptin and its combination therapies. Sitagliptin, first introduced in India in 2008, has played a key role in managing type 2 diabetes by lowering HbA1c levels and improving blood sugar control. Despite rising competition from generics, MSD has maintained a strong position in the value segment of this category.